Phase I study confirms safety and tolerability of AC102 in patients with sudden hearing loss This is another important milestone that clears the way for a Phase 2 study evaluating AC102 in patients with sudden hearing loss Berlin, 7 September 2021 – AudioCure...
The FDA has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may become of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL). Comprehensive...
Berlin, 3 March 2021 – The 3rd of March is World Hearing Day. On the occasion the World Health Organization (WHO) issued its first World Report on Hearing. Hearing disorders are known to be a global problem. The WHO however warns that by 2050 nearly 2.5 billion people...
Phase I trial to assess safety, tolerability and pharmacokinetics of AC102-suspension after application into the middle ear of healthy volunteers Milestone achievement for AudioCure Pharma on its way to combating hearing loss disorders with unmet medical need Berlin,...
AudioCure has made exciting progress in its preclinical program by extending both its indication and compound pipelines in recent months. We are very pleased to announce that we have therefore extended our scientific team to continue pushing our preclinical...
The EMA’s Committee for Orphan Medicinal Products has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may be of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural...
This website uses cookies. By clicking on the “Ok” button, you consent to our use of cookies as described in our Privacy Notice. If you continue to use this site we will assume that you agree with our Privacy Police.OkRead more
